Polaprezinc is a chelated form of zinc and L-carnosine. It is a zinc-related medicine approved for the first time in Japan, which has been clinically used to treat gastric ulcers... It was determined that polaprezinc may be effective in pressure ulcer treatment.
- Mechanism
- Curator reviewed · 1 reference
Polaprezinc increases the expression of various antioxidant enzymes, including superoxide dismutase 1 (SOD-1), SOD-2, heme oxygenase-1 (HO-1), glutathione S-transferase (GST), glutathione peroxidase (GSH-px), peroxidredoxin-1 (PRDX1; PRXI) and PRXD5 (PRXV).
This process occurs in the gastric mucosa, defending mucosal cells against reactive oxygen species. This drug inhibits the activity of the transcription factor nuclear factor-kappaB (NF-kB) and decreases the expression of various inflammatory cytokines, including interleukin (IL) 1beta, IL-6, IL-8, and tumor necrosis factor alpha (TNF-a).
Polaprezinc also promotes the expression of numerous growth factors, including as platelet-derived growth factor-B (PDGF-B), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), in addition to various heat shock proteins (HSPs), including HSP90, HSP70, HSP60, HSP47, HSP27, and HSP10. This process promotes tissue growth and protects against damage the gastric mucosa.
- Primary indication
- Peptic ulcer disease, dyspepsia.Curator reviewed
- Formula / weight
- C9H12N4O3Zn · 289.6 g/mol (avg)
- Code names
- Z-103
Resolves to
IGXZLYMCFZHNKW-FJXQXJEOSA-LSMILESNCCC(=O)N1[Zn]OC(=O)[C@@H]1CC1=CN=CN1What you can answer from here — as of March 06, 2025
Which drugs share a target with Polaprezinc, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account